Introduction
The spread of HIV infection world wide has generated an urgent need to test a large number of compounds which may have activity against this virus. Evaluation ranges from in vitro enzymatic assays based on recombinant technology, to testing directly against HIV in tissue culture: Resubmitted 2 October, 1991; revised 28 October, 1991 . 'For correspondence: Department of Chemistry, University of Southampton, Highfield, Southampton, S09 5NH. Tel. any promising compounds may then be tested in vivo. Necessary test systems include feline, primate, and other animal lentiviruses which are currently proving useful in a number of respects particularly in the exploration of strategies for production of vaccines (Daniel and Desrosiers, 1989; Stott et al., 1990; Jarrett et al., 1991) . However, a small retroviral model system for HIV infection would be a valuable asset in the assessment of antiretroviral drugs and in the understanding of the immunopathology of AIDS.
Although no lentivirus has yet been isolated from mice, several murine oncornavirus model systems have proved useful in the evaluation of certain antiviral drugs directed against HIV (Gardner, 1990) . Among these is the immunosuppressive urethane leukaemia virus (ULV) (Salaman, 1963 ), and we have described those characteristics which lead us to consider ULV infection of mice to be a suitable model for testing drugs directed against HIV (Harvey et al., 1990) . Moreover, recent evidence supports the hypothesis that infections by HIV or murine immunosuppressive retrovirus may cause a common fundamental' defect at early stages of the immune response (Knight et el., 1991) . In vivo the antiViral effectiveness of AZT against murine oncornaviruses, (including ULV),is greatest when given at, or soon after infection. More recently this has been confirmed using HIV in the SCID-hu mouse (Shih et al., 1991) . These results lend weight to the relevance of model systems, including murine oncornavirus studies. Ruprecht (1990a) has suggested schedules for the testing of new antivirals which at an early stage includes murine retrovirus(es) in vitro and in vivo.
The inhibitory effect of 3'-azido-3'-deoxythymidine (AZT) against MuLV is well known (Krieg et al., 1978) and the sensitivities of HIV and MuLV to AZT have been compared in various assay systems in vitro (Balzarini et al., 1988 (Balzarini et al., , 1989 Ruprecht et al., 1990b; Mansuri et al., 1990) . In the sarcoma positive, leukaemia negative (S+ L-) assay for MuLV described by Bassin (1971) foci of phenotypically changed mouse cells, observed 5-6 dafter infection were in direct proportion to the MuLV titres employed. Since we wish to use murine oncornavirus test systems in vivo we describe here the successful use of the S+L-assay. This is a sensitive, quick, and reproducible method in vitro for preliminary antiviral assessment of new nucleotide derivatives, which we have compared with AZT in parallel with in vitro tests against HIV.
Results
Diamidate derivatives 1a-1 g were prepared exactly as described previously (Jones et al., 1991) ,by a modification of the Yoshikawa reaction (yoshikawa et al., 1967) . Thus, AZT was allowed to react with phosphoryl chloride in dry triethyl phosphate in the cold to produce the intermediate nucleoside phosphorodichloridate, which was neither isolated nor characterized. This was then allowed to react simply with the appropriate amine (1f-1g), or the appropriate amino acid methyl ester hydrochloride along with triethylamine (1 a-1 e).
The amidate analogues were prepared by a more straightforward strategy, involving the preparation of the appropriate alkyl phosphorodichloridate, and its reaction with an amino acid methyl ester to give the phosphoramidate, which was then reacted with AZT. Compounds 2a-2c were prepared exactly as described previously . Table 1 . Activity of compounds against HIV 1 and MuLV. In the HIV assay the ICso is that concentration of drug, in fLM, at which viral antigen in the supernatant is reduced by 50%. All drugs were tested for cytotoxicity by measuring 14Cprotein hydrolysate uptake by the target cells, the maximum concentration tested (in fLM) being shown in brackets. In the MuLV assay the IC so is that concentration of drug at which virus-induced foci were reduced by 50%. Because of the larger volumes of culture fluid used in the S+L-assay, it is only possible, in some cases, to state the range in which the ICso values fall. Cytotoxicity was measured by the formation of (uninfected) cell monolayers in the presence of each compound, tested up to the maximum concentration shown in brackets in each case.
Compound
HIV 1 Compounds 2d-2e probe the effect of stereochemistry at the phosphorus atom on biological activity. The synthetic procedure employed gives compounds which are stereochemically pure at every chiral centre other than the phosphorus; where mixed stereochemistry leads to the generation of a diastereomeric pair. It is quite likely that separate isomers of each compound might have quite different biological activity. Indeed, we have noted some initial data on the separate isomers of compound 2c, where the partly purified 'fast' and 'slow' fractions of 2c appear to differ in anti-HIV activity by a factor of approximately three , the more lipophilic isomer being less active. Thus, in the case of 2d-2e, the previously reported 1 :1 mixture of isomers of the ethyl methoxyvalinyl compound was separated entirely into its pure constituents by High Performance Liquid Chromatography (HPLC),2d being the 'fast' (more lipophilic) isomer. The mixture of isomers gave two closely spaced peaks in the 31 P nmr spectrum, whereas the separate isomers each displayed one signal, that for 2d being the furthest downfield.
Compound (2f) was prepared as described previously . This haloalkyl substituted analogue of compound (2a) is a particularly interesting compound, in that it is very much more active against HIV-1 in C8166 cells than would be anticipated on the basis of Ourestablished structure activity relationships.
Compounds (2g-2h) are entirely new, and probe the effect of structural variation in an area of the molecule we have not varied previously. Thus, the compounds are benzyl ester analogues of the usual methyl esters, (2g) being the analogue of (2a), and (2h) the analogue of the lead compound (2f).Replacement of the methyl group by a benzyl might well be expected to greatly modify biological properties, on the basis of substantial differences in both their steric and electronic properties. Compounds (2g-2h) were prepared by methods entirely analogous to those employed for the analogues (2a, 2f) and were fully characterized by analytical and spectroscopic methods. Compounds were evaluated for their inhibitory effect on MuLV and HIV 1. The results are presented in Table 1 . Table 1 . It should be noted that no active anti-HIV compounds are missed in the MuLV system, (a result which is expected, since the antivirals are directed against products of conserved regions of the viral genomes). Indeed, the most effective compounds against HIV-1 tend to be the most potent against ULV, and vice versa. The prototype compound AZT is consistently ten-fold more active against ULV than HIV, and in almost every case the phosphate derivatives are either more active against MuLV, or equally active against the two viruses. The only exception is compound (1 d) which, it appears, is slightly more effective against HIV, an unexpected result which would not have been predicted from established structure activity relationships and may indicate a novel mode of action. It is noteworthy that some compounds were cytotoxic in the S+L-cells; a toxicity which was not detected in the HIV assay.
Discussion

A comparison of activities against HIV and MuLV is listed in
The greater antiviral activity of these compounds against ULV when compared with HIV may be due to increased efficiency of the S+ L-cells in phosphorylating the nucleosides to the bio-active triphosphate forms. This is in agreement with work with other murine cells, which showed that phosphorylation of AZT was not blocked at the monophosphate level, and consequently higher concentrations of intracellular AZT triphosphate were formed (Balzarini et al., 1988) . These differences in phosphorylation between the two systems may require further clarification. The efficiency of phosphorylation by the S+L-cells is also reflected in the levels of input virus in the two systems: although difficult to compare directly, virus input in the' ULV system is higher. Apart from the greater vulnerability of S+L-cells to some cytotoxicity, ULV in S+L-cells is highly sensitive to AZT and its derivatives in vitro. These observations indicate that it is a useful parallel screen for such reversetranscriptase inhibitors, possibly helping to identify those which exert their antiviral effects in a novel way. We are currently adapting the S+L-assay to smaller culture dishes, which will be of value where quantities of drug are limited.
We have also compared the activity of AZT with that of some of these derivatives against ULV in vivo. Preliminary data show that the amidates and diamidates are active, but not toxic, in vivo. Although not as active as AZT, all of the compounds tested had some protective effect against the results of virus infection, both splenomegaly and virus expression insplenocytes being less in treated mice. With regard to anti-HIV activity per se, the data in Table. 1 confirm our earlier observations concerning the dominant structure activity relationships in operation for these compounds McGuigan eet al., 1990; Jones et al., 1991; McGuigan et al., 1991) . However, two new observations emerge; firstly, the very noticeable effect of phosphorus stereochemistry on biological activity is highlighted by compounds (2d)and {2e):There is a tenfold difference in activity between the two isomers, the most lipophilic being the most active. This compound was tested previously as a 1: 1 mixture of diastereoisomers about the phosphorus centre, with an IC so (1 0 j.LM) intermediate between that of (2d) and (2e) . This reinforces our conclusion that the precise environment at the phosphorus-nitrogen bond is crucial for the antiviral properties of these compounds; a finding which is consistent with the suggestion of P-N cleavage as a mode of activation. The second observation concerns the benzyl esters, herein reported for the first time. Thus, compound (2h) is the benzyl ester of our promising lead compound (2f). It is noticeable that the unusuallyhiqh activity of (2f) is retained, and indeed possibly increased Zidovudine amidates and diamidates 109 slightly, on comparing the benyzl ester with its methyl analogue. The origins of the high activity of (2f)and (2h)are being pursued in our laboratory.
Materials and Experimental procedures: Chemistry
All reactions were carried out under scrupulously dry conditions unless otherwise 1ndicated. Reagents were dried as follows before use: diethyl ether was distilled from CaH 2 onto activated 3A molecular sieves. THF was distilled from Na/benzophenone under nitrogen. N-Methylimidazole was heated to 100°C over CaH 2 for 4 h and then distilled at 15 mm Hg. AZT was dried at ca. 50°C 0.1 mrn" Hg for several hours before use. For flash column chromatography Woelm 32-63 silica was used. Proton nmr spectra were recorded on a Varian ZL200 spectrometer operating at 200MHz or a Varian VXR400 operating at 400 MHz. 31p nmr spectra were obtained on these instruments, operating at 81 MHz and 162 MHz respectively. 13C spectra were recorded on the latter instrument at 100 MHz. Proton spectra were referenced to TMS, phosphorus spectra to 85% phosphoric acid, and carbon spectra to COCI 3; positive shifts are downfield of the reference. Microanalyses were performed at UCL, in the laboratory of Mr A. Stones. The triesters were analysed by HPLC prior to biological evaluation and were free of AZT (ACS system using a 50 + 250 x 4.6mm Spherisorb 00S2 5/LM-1 column (ACS, Macclesfield, Cheshire, UK) and a mobile phase of water (A) and 5% water in acetonitrile (8), with 82% (A)at 0-10 min and then a Iineargradient to 20% (A) at 30 min, with a flow rate of 1.0ml mlrr", and detection by UV at 254 nm). Compounds not described below were prepared entirely as described by us in the recent references. cited herein.For spectroscopic data on the compounds reported for the first time, see the appendix.
. Separated isomers of 3' -Azido-3'-deoxythymidine-5'-(ethyl methoxyvallnyh phosphate (2d, 2e) . The mixed isomers were prepared exactly as described previously . These were separated by preparative HPLC on a Waters system, using 250 x 4.6 mm Partisil5 silica column, and a mobile phase of 90% ethyl acetate/10% petroleum spirit, with a flow rate of 2 ml min-1. Samples containing the 'fast' fraction were pooled and evaporated under reduced pressure to yield (2d) as an oil. The 'slow' sample (2e) was similarly isolated.
-Ethyl benzylalaninyl phosphorochloridate. L-Alanine benzyl ester (1.16g, 6.47mmol) in anhydrous diethyl ether (5ml) was added dropwise with Vigorous stirring to a solution of ethyl phosphorodichloridate (0.33ml, 2.83 mmol) in diethyl ether (10 ml) at -40°C. The reaction mixture was allowed to warm to ambient temperature, with stirring for 3 h, and thenfiltersd. The filtrate was concentrated in vacuo, to give the product as a pale yellow oil (0.99g, 98%).
3' -Azido-3'-deoxythymidine-5'-(ethyl benzylalaninyl) phosphate (2g). 3'-Azido-3'-deoxythymidine (0.11g, 0.41 mmol) and ethyl benzylalaninyl phosphorochloridate (0.92g, 2.88mmol) were stirred together in anhydrous tetrahydrofuran (THF) (5ml) containing N-methylimidazole (0.46ml, 5.76mmol) for 16h, at ambient temperature. The solvent was removed invacuo, and the residue dissolved in chloroform (30ml), and extracted with saturated sodium bicarbonate solution (15ml), and water (2 x 15ml). The organic phase was dried (MgS0 4 ) and evaporated in vacuo. The residue was re-dissolved in chloroform (10ml), and precipitated with petroleum (bp 3D-40°C) (400ml).The precipitate was purified by chromatography on silica gel (30g), using 4% methanol in chloroform as eluant. Pooling and evaporation of appropriate fractions gave the pure product (0.06g, 28%).
2,2,2-trichloroethyl benzylalaninyl phosphorochloridate. A solution of triethylamine (0.32 rnl, 2.33 mmol) in dichloromethane (20 ml) was added very slowly, dropwise with vigorous stirring to a solution of L-alanine benzyl ester hydrochloride (0.50g, 2.33mmol) and 2,2,2-trichloroethyl phosphorodichloridate (0.75g, 2.79mmol) in dichloromethane (20ml) at -78°C, and the reaction was allowed to warm to room temperature over a period of 4 h. The solvent was removed in vacuo, and the residue treated with carbon tetrachloride (20ml). Filtration and evaporation of the filtrate in vacuo, followed by trituration with n-hexane (2 x 20ml) gave the product as a colourless oil (0.55g, 58%).
3' -Azidothyrnldlne-S' -(2,2,2-trichloroethyl benzylalaninyl) phosphate (2h). 2,2,2-Trichloroethyl benzylalaninyl phosphorochloridate (0.54g, 1.34mmol) was added to a solution of AZT (0.07g, 0.27 mmol) in anhydrous THF (3ml) containing N-methylimidazole (0.22 rnl, 2.70 mmol), the mixture stirred for 16 h at ambient temperature. The solvent was removed under reduced pressure, and the residue dissolved in chloroform (30ml), and extracted with saturated sodium bicarbonate solution (15ml), and then with water (2 x 10 ml). The organic phase was dried over magnesium sulphate, and concentrated under reduced pressure. The residue was precipitated from chloroform (10ml), by the addition of petroleum ether (300ml; bp 30--40). The product was then purified by flash column chromatography on silica gel, using 5% methanol in chloroform as eluant. Pooling and evaporation of appropriate fractions gave a product which was pure by TLC and spectroscopy, but contained traces «0.3%) of AZT. A small sample for biological evaluation was further purified by preparative HPLC, using an acetonitrile-water gradient.
Materials and Experimental procedures: Virology
Antigen reduction assay for Iymphablastaid cells acutely infected with HIV
High titre virus stocks (HIV 1 RF) were prepared from chronically infected H9 cells grown in RPMI 1640 (Flow Laboratories, High Wycombe, Buck, UK) supplemented with 10% fetal calf serum. Cell debris was removed by low speed centrifugation and the supernatant fluid stored in liquid nitrogen until required. The cells used in these assays were the C8166 T-Iymphoblastoid line. Cells were infected with 10 TCID50 HIV 1 (RF) at 37°C for 90 min and washed 3 times with PBSA. 2 x lO s cells per well were resuspended in 1.5 ml of growth in medium in 6 ml Falcon tubes for each compound at half log dilutions from 0.01 to 100 JLM and incubated at 37°C for 72 h in a 95% air: 5% CO 2 atmosphere. The HIV antigen was measured in the supernatants with a commercial ELISA using the steps described by the manufacturer (Coulter Electronics Ltd, Luton, Beds, UK) (Kinchington et al., 1989) . AZT and ddCyd (Roche Products Ltd., Welwyn Garden City, Herts, UK) were used as internal controls, together with infected untreated cells and uninfected cells. Assays were carried out in duplicate and experiments were undertaken on at least tWQ different occasions. To test for compound toxicity, 2 x lO s uninfected cells per well were cultured with the compounds at the same half log dilutions for 72 h. The cells were then washed with PBSA and resuspended in 200 JLI of growth medium containing 14Cprotein hydrolysate. The cells were harvested after 16h and the 14C incorporation measured. Untreated cells were used as controls.
S+L-assay for murine leukaemia viruses
One day before the assay, 10mM stock solutions of the drugs, including AZT, were prepared in DMSO or 25% DMSO in water, and aliquots were stored at -20°C. For comparative purposes a range of dilutions of drugs was selected on the basis of their ICso values obtained previously against HIV. Just prior to use in the assay these dilutions were prepared in tissue culture medium and adjusted so as to give a concentration of 1% (as used in the HIV assay) or 0.3% DMSO throughout. Assays were repeated at least twice, and 3 or 4 times where quantities of drug permitted. Appropriate DMSO controls were included in the assay, which was conducted as described (Bassin et al., 1971, and personal communication) . In the assay, the medium was McCoy's modified (GIBCO, Grand Island, NY, USA) with 10% fetal calf serum, penicillin and streptomycin (100iu rnl"), and glutamine. S+L-(D56) cells were plated at 1 x 10 s per 60 mm (gridded) petri dish (NUNC, Roskilde, Denmark) in 4ml medium and incubated at 3rC in a CO 2 incubator (5-6% COd. At this low seeding rate care was taken to disperse the cells evenly. Twenty-four hours later, medium was removed and duplicate 0.5ml virus dilutions, freshly prepared in cold medium quickly added per plate. Three log 10 dilutions of a standard MuLV preparation were chosen. These were known to give at high concentration confluent phenotypic change, and at low concentration readily countable foci. Therefore, multiplicity of infection was 1 FFU: 29 cells, 1 FFU: 296 cells, and 1 FFU: 2856 cells. Virus-infected and control plates were incubated for 1 h during which time the plates were rocked at 15 min intervals, to ensure distribution of fluid across the cells. The dilutions of freshly prepared drugs or control fluids were added, 4 ml per plate, and incubated. All assays of test drugs included a comparison with 3 concentrations of AZT, also untreated S+Lcells, S+ L-cells with dilutions ottest drug, S+L-cells with drug solvent (DMSO), and S+L-cells with virus alone. Two days later, 4ml of drug or control fluid were added per dish, and incubation continued until foci were counted on day 6 post-infection. Foci were counted usually on viable cells us·ing an inverted microscope at x40 magnification or on plates fixed in methanol, air-dried, then stained with 10% Giemsa in pH 6.8 Giemsa buffer. During the assay all plates were screened dallyusinq an inverted microscope for signs of cytotoxicity, l.e, failure to form monolayers, or slower formation of monolayers than appropriate controls. 1% DMSO slowed monolayer formation and reduced the number of virus-induced foci by half at high virus dilutions, but 0.3% DMSO was well tolerated. By comparison, 1% pMSO was well tolerated by human cells in the. Coulter antigen assay.
Where possible, and for comparative purposes with the HIV assay, S+L-assays were performed at both concentrations of DMSO; based on appropriate DMSO controls, drugs tested had the same IC so against the virus. For HIV the virus input was 10 syncytia-forming units: 2 x 10 s cells (1:20000) iNhilefor ULVthe lowest input used was 1 FFU: 2856 cells. ThUS, for the data obtained in table 1 the ULV infectivity levels are about seven-fold higher than that of HIV. However, these infectivity ratios may bear only a notional relationship to actual amounts of infectious virus present. The number of infectious HIV particles involved in forming syncytia in the C8166 cells may be greater than the number of ULV particles needed to produce a plaque in the S+ Lassay. 
